Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer

[1]  M. Mack,et al.  Biologic properties of a bispecific single-chain antibody directed against 17-1A (EpCAM) and CD3: tumor cell-dependent T cell stimulation and cytotoxic activity. , 1997, Journal of immunology.

[2]  M. Mack,et al.  A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[3]  L. de Leij,et al.  Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2. , 1994, British journal of cancer.

[4]  P. D. De Mulder,et al.  Cytokine release in an ovarian carcinoma patient following intravenous administration of bispecific antibody OC/TR F(ab')2. , 1993, Journal of the National Cancer Institute.

[5]  T. Yokota,et al.  Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. , 1992, Cancer research.

[6]  G. Riethmüller,et al.  The epithelial cell surface antigen 17–1A, a target for antibody‐mediated tumor therapy: Its biochemical nature, tissue distribution and recognition by different monoclonal antibodies , 1986, International journal of cancer.

[7]  J. Bluestone,et al.  Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody , 1985, Nature.

[8]  Osami Kanagawa,et al.  Hybrid antibodies can target sites for attack by T cells , 1985, Nature.

[9]  H. Koprowski,et al.  Binding of murine immunoglobulin to human tissues after immunotherapy with anticolorectal carcinoma monoclonal antibody , 1984, International journal of cancer.